Tau protein undergoes conformational changes and abnormal phosphorylation, which leads to its separation from microtubules, forming neurofibrillary tangles
Includes a Microdose GLP-1 program with SmartDose titration for a slower, more gradual path into treatment
Based on typical FDA review timelines and the current progress of trials, analysts project: Phase 3 trial completion: Late 2025 to early 2026 FDA submission: First half of 2026 Potential FDA approval: Q3 2026 to Q1 2027 Commercial availability: 2-3 months post-approval The FDA has not granted any special designations (Breakthrough Therapy, Fast Track) for Retatrutides obesity indication, which may mean standard review timelines apply
Liposomal glutathione from a unique process allowing the properties of glutathione to be preserved (without heat, without pressure, without chemicals, without preservatives)
At the 12mg dose, participants lost an average of 24.2% of their body weight in just 48 weeks
The armpit lump should reduce in size and eventually disappear